OnCore Biopharma

OnCore Biopharma
Name	OnCore Biopharma
Industry	Biotechnology
Founded	2019
Headquarters	Philadelphia, Pennsylvania
Key people	Jeffrey Paul; Eric K. Rowe; Linda A. Griffith
Products	Small molecules; Biologics; Oncology therapeutics
Revenue	Private

OnCore Biopharma is a biotechnology company focused on developing targeted therapies and diagnostics for oncology and inflammatory diseases. Founded in 2019, the company has pursued drug discovery, translational research, and clinical development with a strategy combining small molecule chemistry, biologics, and companion diagnostics. OnCore engages with academic institutions, contract research organizations, and pharmaceutical companies to advance its pipeline through preclinical and clinical stages.

History

OnCore Biopharma was founded in 2019 amid a wave of biotechnology startups emerging from translational research programs at institutions such as University of Pennsylvania, Harvard University, Massachusetts Institute of Technology, Stanford University, and Johns Hopkins University. Early seed financing involved venture capital firms linked to Flagship Pioneering, Third Rock Ventures, OrbiMed Advisors, and Atlas Venture. The company established research collaborations with research hospitals including Children's Hospital of Philadelphia, Dana–Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and Mayo Clinic. Strategic hires included scientists with prior experience at Genentech, Amgen, Pfizer, Merck & Co., and Bristol-Myers Squibb. Regulatory interactions have involved offices such as the U.S. Food and Drug Administration, and the company pursued Investigational New Drug applications following preclinical work consistent with guidelines from the European Medicines Agency and Medicines and Healthcare products Regulatory Agency.

Corporate structure and leadership

OnCore Biopharma's corporate governance includes a board of directors with members drawn from biotech finance and pharmaceutical development circles including executives formerly at Gilead Sciences, Novo Nordisk, Eli Lilly and Company, Celgene, and Regeneron Pharmaceuticals. The executive leadership team has roles such as Chief Executive Officer, Chief Scientific Officer, Chief Medical Officer, and Chief Financial Officer, with reporting lines to investor committees from Sequoia Capital, Accel Partners, and Sofinnova Partners. Legal and compliance oversight engages law firms with experience in life sciences such as Skadden, Arps, Slate, Meagher & Flom, WilmerHale, and Covington & Burling. Operational functions utilize contract manufacturing organizations like Catalent, Lonza Group, and Thermo Fisher Scientific for biologics and small molecule production.

Research and development

OnCore's R&D strategy blends medicinal chemistry, structural biology, and translational oncology, leveraging platforms from groups at Broad Institute, Cold Spring Harbor Laboratory, Salk Institute, and Scripps Research. Preclinical models include collaborations with animal research centers like Jackson Laboratory and CROs such as Charles River Laboratories and LabCorp (Covance). In vitro screening employs technologies from Illumina, Thermo Fisher Scientific, and Agilent Technologies, while proteomics and mass spectrometry workflows draw on instruments by Thermo Fisher Scientific and Bruker Corporation. Target validation used CRISPR tools pioneered by labs at MIT, UC Berkeley, and Geneva University Hospital (HUG), and biomarker discovery partnered with Foundation Medicine and Guardant Health for circulating tumor DNA assays. OnCore's translational teams interacted with principal investigators from Yale School of Medicine, UCLA Health, University of Chicago Medicine, and NYU Langone Health to design early-phase clinical trials.

Pipeline and products

The company advanced multiple candidates across oncology indications such as solid tumors, hematologic malignancies, and tumor microenvironment targets, with therapeutic modalities including kinase inhibitors, immunomodulators, and antibody–drug conjugates. Preclinical candidates were benchmarked against standards from Novartis, AstraZeneca, Roche, Takeda, and Sanofi. Companion diagnostic efforts were informed by assays developed by Roche Diagnostics, Abbott Laboratories, and Qiagen. Clinical-stage programs entered Phase I/II trials at centers including MD Anderson Cancer Center, Cleveland Clinic, and UC San Diego Health. The portfolio management referenced data from pivotal trials like those conducted by KEYTRUDA-sponsors and comparator arms from studies led by CheckMate investigators.

Collaborations and partnerships

OnCore formed partnerships with pharmaceutical companies, academic consortia, and nonprofit foundations such as The Leukemia & Lymphoma Society, American Cancer Society, and Stand Up To Cancer. Industry collaborations involved licensing and codevelopment agreements with firms including Bayer, Boehringer Ingelheim, Takeda Pharmaceutical Company, and specialty biotech firms spun out of Emulate Inc. and Alnylam Pharmaceuticals. Research alliances included technology transfers from MIT Technology Licensing Office, Harvard Office of Technology Development, and Penn Center for Innovation, and joint programs with translational networks such as NCI-designated cancer centers and the Clinical and Translational Science Awards consortium.

Financial performance and transactions

As a privately held company, OnCore raised capital through multiple financing rounds led by venture capital firms and strategic investors, with participation from corporate venture arms tied to Johnson & Johnson Innovation, Pfizer Ventures, and Takeda Ventures USA. Transaction activity included licensing deals, option agreements, and milestone payments with midsize biopharma partners and academic licensors represented by Kirkland & Ellis and Goodwin Procter. Financial reporting to investors referenced valuation precedents from recent biotech IPOs like Beam Therapeutics, Sana Biotechnology, and CRISPR Therapeutics while benchmarking exit scenarios to acquisitions such as Gilead's purchase of Kite Pharma and Bristol-Myers Squibb's acquisition of Celgene. Operational financing utilized debt facilities from life sciences lenders and terms negotiated with banks active in the sector.

Category:Biotechnology companies